HILDEN, Germany & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus Inc., the leader in cloud-based genome informatics and data management, today announced that QIAGEN, a leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights, has integrated the DNAnexus cloud genomics platform with Ingenuity Variant Analysis, QIAGEN’s leading variant interpretation solution. Researchers globally now have the ability to choose a sequencer independent, cloud-based solution for analyzing and interpreting their NGS data by uploading raw sequencing data into the scalable DNAnexus cloud platform and seamlessly generating uniquely actionable biological insights through QIAGEN’s Ingenuity Variant Analysis.
“Adoption of QIAGEN’s universal bioinformatics solutions is growing rapidly as NGS becomes the norm for translational research in cancer and other diseases,” said Dr. Frank Schacherer, Vice President Discovery Genomics at QIAGEN. “The HIPAA-compliant DNAnexus Platform provides seamless and secure integration from the sequencer to QIAGEN bioinformatics tools where disease-focused researchers now have a complete solution to move rapidly from raw data to valuable insights.”
Ingenuity Variant Analysis leverages expert, manually-curated literature and powerful Path-to-Phenotype™ capabilities to relate biological phenotype with human variation data. The DNAnexus Platform enables QIAGEN to run best practices secondary analysis in the cloud, providing a secure, reproducible, cost-effective, and scalable solution. In addition, the DNAnexus export tool enables customers to securely transfer variant data into QIAGEN’s Ingenuity platform automatically for downstream analysis, including annotation, interpretation, and variant reporting. Furthermore, while exploring variants inside of Variant Analysis, researchers can easily refer back to supporting information such as the mapped reads found in a BAM file on DNAnexus, and view this data along with the variant data inside of a genome browser. This integrated solution allows researchers to rapidly identify, prioritize, and validate the most promising variants for follow-up. Dr. Schacherer will be in attendance at this year’s American Society for Human Genetics in Baltimore to further discuss details of the partnership to Society members.
“The DNAnexus Platform is becoming the go-to solution for data interpretation tool providers who are seeking a secure, compliant, and scalable environment on which they can deploy and expand their product offerings,” said Richard Daly, CEO of DNAnexus. “We are proud of the collaboration with QIAGEN, which allows clinical researchers to move seamlessly between the two environments providing a powerful new end-to-end analytical solution for genomic biomarker discovery and interpretation.”
By providing the global network for genomic medicine, DNAnexus is removing barriers to genomic insight; whether those barriers are geographic boundaries that hinder collaborating across national borders, disparate organizations sharing and analyzing data together, or financial barriers for customers not looking to invest in additional IT infrastructure.
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. For more information please visit: https://dnanexus.com and follow us at @DNAnexus.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2015, QIAGEN employed approximately 4,400 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.